Eric J. Topol

1 week ago | community.thriveglobal.com | Eric J. Topol

For many years, my colleagues and I have been fascinated by individuals like Mrs. L. R., who are so lucky to be so resilient to diseases. In 2008, we set up a research project called “Wellderly,” to study people who were at least eighty years old and had never been sick or had a chronic illness.

1 week ago | kevinmd.com | Eric J. Topol |Gjanje L. Smith |Wanneh A. Dixon |Maria Phillips

An excerpt from Super Agers: An Evidence-Based Approach to Longevity. For many years, my colleagues and I have been fascinated by individuals like Mrs. L. R., who are so lucky to be so resilient to diseases. In 2008, we set up a research project called “Wellderly,” to study people who were at least eighty years old and had never been sick or had a chronic illness.

1 week ago | erictopol.substack.com | Eric J. Topol

Audio FileAudio playback is not supported on your browser. Please upgrade. Ground Truths can also be found on Apple Podcasts, Spotify and YouTube. The UK is the world leader in human genomics, and laid the foundation for advancing medicine with the UK Biobank, Genomes England and now Our Future Health (w/ 5 million participants). Sir John Bell is a major force in driving and advising these and many other initiatives.

2 weeks ago | medcentral.com | Eric J. Topol |Ivan Oransky

In this timely interview, Eric Topol, MD, discusses with Ivan Oransky, MD, key clinical takeaways from his new book, Super Agers: An Evidence-Based Approach to Longevity, published this month by Simon & Schuster. On the docket: what physicians can do now to help prevent the top three age-related diseases – cardiovascular disease, cancer, and neurodegenerative disease – in their patients, the overlooked role of the immune system, and why GLP-1s are outperforming all expectations.

2 weeks ago | erictopol.substack.com | Eric J. Topol

A landmark event in medicine was reported this week that has implications well beyond its likelihood of saving a baby’s life. Until now, commercially available CRISPR genome editing (Casgevy) was not capable of directly fixing a genomic defect. It was a workaround plan, that can be regarded as CRISPR 1.0. In this edition of Ground Truths, I’m going to take you through the advances in genome editing and why the new case report at NEJM heralds an extraordinary opportunity for the future of medicine.